Net Income (Loss) [USD, thousands]

Remeasurement of Derivative Instruments [USD, thousands]

Stock-based Compensation [USD, thousands]

Depreciation [USD, thousands]

Amortization of Debt Issuance Costs [USD, thousands]

Amortization of Intangible Assets [USD, thousands]

Amortization of Operating Lease Assets [USD, thousands]

Other Adjustments to Reconcile Net Income (Loss) [USD, thousands]

Deferred Income Tax Expense (Benefit) [USD, thousands]

Remeasurement of Contingent Consideration to Fair Value [USD, thousands]

Loss on Debt Extinguishment [USD, thousands]

Changes in Accounts Receivable, Net [USD, thousands]

Changes in Inventories [USD, thousands]

Changes in Other Current and Non-current Assets [USD, thousands]

Changes in Accounts Payable and Accrued Current and Non-current Liabilities [USD, thousands]

Changes in Taxes Payable [USD, thousands]

Changes in Litigation Provision Liability [USD, thousands]

Net Cash Provided by Operating Activities [USD, thousands]

Purchases of Property, Plant and Equipment [USD, thousands]

Other Investing Activities [USD, thousands]

Net Cash Used in Investing Activities [USD, thousands]

Proceeds from Long-term Debt Obligations [USD, thousands]

Repayment of Long-term Debt Obligations [USD, thousands]

Payment of Debt Extinguishment Costs [USD, thousands]

Purchase of Capped Calls [USD, thousands]

Proceeds from Unwind of Capped Calls [USD, thousands]

Payment of Contingent Consideration [USD, thousands]

Payment of Debt Issuance Costs [USD, thousands]

Other Financing Activities [USD, thousands]

Net Cash Provided by (Used in) Financing Activities [USD, thousands]

Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash [USD, thousands]

Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash [USD, thousands]

Cash, Cash Equivalents and Restricted Cash at Beginning of Period [USD, thousands]

Cash, Cash Equivalents and Restricted Cash at End of Period [USD, thousands]

5a0586055ba8cd4b08fd40806bf985cd1868c0b4c62369be3a6ada92577aca81

Total Revenue (USD, thousands)

Cost of Goods Sold (COGS) (USD, thousands)

SG&A (USD, thousands)

R&D (USD, thousands)

D&A (USD, thousands)

Interest Expense (USD, thousands)

Operating Income (EBIT) (USD, thousands)

Net Income (USD, thousands)

EPS - Basic (USD)

EPS - Diluted (USD)

762a7ff4513c9f81f1faaac614a727fcad33ed4a9aa34039178e8b0d3e522c79

Adjustments for Non-Cash Items (USD, thousands)

Stock-Based Compensation (USD, thousands)

Changes in Working Capital (USD, thousands)

Capital Expenditures (CapEx) (USD, thousands)

Proceeds from / Repayments of Debt (USD, thousands)

Share Repurchases (USD, thousands)

Dividend Payments (USD, thousands)

Net Change in Cash (USD, thousands)

0c3e319bcc0c09da16c21f460e4d0ccf53c15d9bd92ac787adb4391cb7961a83

Current Assets (USD, thousands)

Cash and Cash Equivalents (USD, thousands)

Accounts Receivable (USD, thousands)

Inventory (USD, thousands)

Non-Current Assets (USD, thousands)

Property, Plant, and Equipment (PP&E) (USD, thousands)

Goodwill (USD, thousands)

Intangible Assets (USD, thousands)

Current Liabilities (USD, thousands)

Accounts Payable (USD, thousands)

Short-term Debt (USD, thousands)

Accrued Expenses (USD, thousands)

Non-Current Liabilities (USD, thousands)

Long-term Debt (USD, thousands)

Lease Liabilities (USD, thousands)

Deferred Tax Liabilities (USD, thousands)

Shareholders' Equity (USD, thousands)

Retained Earnings (USD, thousands)

Common Stock (USD, thousands)

Additional Paid-in Capital (USD, thousands)

65c75cc4f055f65dd0b46eeba7b9c98f288b564c06cbfc609d010a98d103e22a

Cardiopulmonary

Neuromodulation

Advanced Circulatory Support (ACS)

Other Revenue

Total Revenue

ac26f835b18500e5dbbb969769d5f0b6e6dc947c12b1bc7b673f15b2dfd8b76a

United States

Europe

Rest of World

- Cardiopulmonary Revenue - United States

- Cardiopulmonary Revenue - Europe

- Cardiopulmonary Revenue - Rest of World

- Neuromodulation Revenue - United States

- Neuromodulation Revenue - Europe

- Neuromodulation Revenue - Rest of World

9fecf89b3da45110d3973b9ff00396c83e691042fa8a1ed1be687514b95b194e

Net revenue (USD, thousands)

Cost of sales (USD, thousands)

Gross profit (USD, thousands)

Selling, general, and administrative (USD, thousands)

Research and development (USD, thousands)

Other operating expenses (USD, thousands)

Operating income (loss) (USD, thousands)

SNIA environmental liability expense (USD, thousands)

Interest expense (USD, thousands)

Loss on debt extinguishment (USD, thousands)

Foreign exchange and other income/(expense) (USD, thousands)

Income (loss) before tax (USD, thousands)

Income tax expense (benefit) (USD, thousands)

Loss from equity method investments (USD, thousands)

Net income (loss) (USD, thousands)

Basic income (loss) per share (USD)

Diluted income (loss) per share (USD)

Shares used in computing basic income (loss) per share (shares)

Shares used in computing diluted income (loss) per share (shares)

fe0705c584938f903ea3d69c8039de18471080886fcc167d3b675ca630375424

75bfff736b6fd586dac9678b2a72ae97e076def8848e55ba7927f1169ed93989

LivaNova PLC (LIVN)

Financials